Navigation Links
New drug target can break down cancer's barrier against treatment
Date:7/27/2014

CANCER RESEARCH UK scientists at Barts Cancer Institute have found that targeting a molecule in blood vessels can make cancer therapy significantly more effective, according to research published in Nature today (Sunday).

The team at Barts Cancer Institute, part of Queen Mary University of London, have found that a molecule, called focal adhesion kinase (FAK), signals the body to repair itself after chemotherapy or radiotherapy, which kill cancer cells by damaging DNA. When the researchers removed FAK from blood vessels that grew in melanoma or lung cancer models, both chemotherapy and radiation therapies were far more effective in killing the tumours.

The researchers also studied samples taken from lymphoma patients. Those with low levels of FAK in their blood vessels were more likely to have complete remission following treatment. This suggests that developing drugs to strike out FAK in cancer blood vessels may boost cancer treatments and prevent cancer from coming back.

Dr Bernardo Tavora, lead author on the paper from the Barts Cancer Institute, said: "This work shows that sensitivity to cancer treatment is related to our own body mistakenly trying to shield the cancer from cell-killing effects caused by radiotherapy and chemotherapy.

"Although taking out FAK from blood vessels won't destroy the cancer by itself, it can remove the barrier cancer uses to protect itself from treatment."

Cells lining the blood vessels send chemical signals, called cytokines, to the tumour to help it resist DNA damage and to recover. The researchers demonstrated that this process requires FAK in order to work, and without it, these signals are never sent making the tumour more vulnerable to DNA damaging therapy.

Dr Kat Arney, Cancer Research UK's science communications manager, said: "This exciting research may have cracked how healthy cells in the blood vessels are protecting against cancer treatments. This research was only done in mice, but it gives real hope that we can boost the effectiveness of cancer medicine and sensitise cancers to the drugs we have."


'/>"/>

Contact: Greg Jones
greg.jones@cancer.org.uk
44-203-469-8311
Cancer Research UK
Source:Eurekalert

Related biology news :

1. Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinsons
2. Potential new flu drugs target immune response, not virus
3. Yale researchers identify targets for immunotherapy in early-stage breast cancer
4. Putting a price tag on the 2° climate target
5. Capturing CO2 emissions needed to meet climate targets
6. Pew and the Stewart Trust launch scholars program targeting cancer
7. New driver of atherosclerosis offers potential as therapeutic target
8. Criminal profiling technique targets killer diseases
9. RNA aptamers targeted to plasminogen activator inhibitor
10. Low dose of targeted drug might improve cancer-killing virus therapy
11. Subseafloor bacteria survive by over-activating DNA-repair and antibiotic target genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... Finland , June 9, 2016 ... National Police deploy Teleste,s video security solution to ensure the ... France during the major tournament ... data communications systems and services, announced today that its video ... Prefecture to back up public safety across the ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
Breaking Biology Technology: